National survey of low-threshold structures (CAARUDs)

Conducted every two years since 2006 in all CAARUDs (Support Centre for the Reduction of Drug-related Harms) on mainland France and in French overseas departments, this survey determines the number of users seen in these structures, the characteristics of these users and their use patterns. Each user who enters into contact with the structure during the survey undergoes a face-to-face interview with someone working at the structure. The questions asked are on use (frequency, age of experimentation, administration route), use-related behaviour (injection, equipment-sharing), screening (HIV, HBV and HCV) and social situation (social coverage, housing, level of education, support from friends and family).

The 2012 survey was conducted from 26 November to 7 December: 4,241 completed or "non-responder" questionnaires were conducted in 142 CAARUDs. After eliminating duplicates (299) and "non-responders" (1,037), 2,905 individuals (in 139 CAARUDs) were included in the analysis.


Overview of CAARUDs in 2014
Tendances n° 113, October 2016

CAARUD client profiles and practices in 2012
Tendances n° 98, January 2015

CAARUD: client profiles and practices in 2008
Tendances n° 74, December 2010

The first national survey on users of the CAARUD centres
Tendances N° 61, May 2008








Drugs in Europe

2018 EMCDDA European Drug Report

EDR2018web.jpgWhat do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students? What are the harms associated with drug use and what is being done to counter them? These and other questions are explored in the 2018 EMCDDA European Drug Report.

  Country drug reports 2017

miniCountryProfiles.jpgDeveloped by the EMCDDA, in cooperation with the Reitox national focal points, these graphic-rich reports cover: drug use and public health problems; drug policy and responses and drug supply.

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.